Anatomy Of A Patent Dispute: Purdue Pharma’s OxyContin Battle
Executive Summary
Two years ago, Purdue Pharma's lawyers anxiously gathered together on a conference call. The U.S. Court of Appeals for the Federal Circuit had just issued its second opinion in OxyContin patent litigation. But the court's earlier ruling had accidentally been posted online. For a tense 20 minutes they waited until one of Purdue's outside attorneys got the final decision
You may also be interested in...
Patent Expiration May Not Help OxyContin Generics
OxyContin’s method of treatment patent expires April 16, but several patents remain tied up in litigation over APIs as Purdue and generic companies await FDA decision on whether the original formulation can be a reference product.
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?